MedTrace Logo

Sarcopenic Obesity in the Elderly

NCT06083909 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 97

Last updated 2023-10-19

No results posted yet for this study

Summary

Ageing is associated with progressive and generalized loss of muscle mass and muscle function, also known as Sarcopenia. Increasingly, obesity has become a compounding factor in ageing-related sarcopenia. The coexistence of obesity and sarcopenia is termed sarcopenic obesity (SO). Older adults with SO are at higher risks of developing diabetes, hypertension, stroke, cardiovascular diseases, and cognitive dysfunction than those older adults who suffer from sarcopenia alone or obesity alone. However, there is insufficient information with regard to the interplay between obesity and sarcopenia. The primary objective of this study is to investigate the impact of SO on insulin resistance in people aged 65-85. Our hypothesis is that SO positively influences insulin resistance in the elderly. We propose to investigate sarcopenia and obesity as risk factors for insulin resistance in the geriatric (65-85 years old) population.

Conditions

Sponsors & Collaborators

  • University of Central Florida

    lead OTHER

Principal Investigators

  • Muthu Periasamy, PhD · University of Central Florida

  • Mariana Dangiolo, MD · University of Central Florida

  • Ali Rizvi, MD · University of Central Florida

Eligibility

Min Age
65 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-06
Primary Completion
2023-04-19
Completion
2023-05-08

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06083909 on ClinicalTrials.gov